(RTTNews) - On Thursday, Agomab Therapeutics (AGMB) reported positive results from the 48-week open-label extension of the Phase 2a STENOVA study evaluating ontunisertib in patients with fibrostenosing Crohn's disease.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.